Given that HSPs may also act as chaperone-kinase-activating pathways, such STAT3 [17], we then evaluated whether HSP inhibition could affect this pathway constitutively activated in PEL cells and strongly involved in their survival. This evidence concerns the gene STAT3 and primary effusion lymphoma.